Australian Broadcasting Corporation
Johnson and Johnson outlines poppy supply plans
Mr Martin was in Tasmania to present its subsidiary, Tasmanian Alkaloids' grower awards, and meet with farmers, members of the company and government representatives.
Fri May 17, 2013
The Washington Post
Johnson & Johnson Ending Sales of Metal-on-Metal Hip Implants
Johnson & Johnson, the world's biggest maker of health-care products, said it will stop selling metal-on-metal and ceramic-on-metal hip replacements as demand wanes for the devices and U.S. regulators seek new rules.
Thu May 16, 2013
Johnson & Johnson: At The Crossroads - Part III
In Part I of "Johnson & Johnson: At The Crossroads", consideration was given to whether a dividend growth rate of 8.2% was sustainable if net income growth rate remained around the projected 6%. It was determined that this gap between dividend and net income growth rates was likely sustainable for at least the next 15 years.
Wed May 15, 2013
The Washington Post
J&J Wins Expanded Approval of Simponi to Treat Bowel Disease
Johnson & Johnson won U.S. approval to use its rheumatoid arthritis drug Simponi to treat patients suffering from a moderate to severe inflammatory bowel disease.
Tue May 14, 2013
Johnson & Johnson Unit Gets Priority Revenue for Simeprevir NDA
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today! Johnson & Johnson unit Janssen Research and Development LLC said the U.S. Food and Drug Administration has granted priority review to its new drug application for simeprevir, its investigational treatment of genotype 1 chronic hepatitis C in adult patients ... (more)
Mon May 13, 2013
Johnson & Johnson (JNJ): What You Should Know
I'm not quite as fanatical as Warren, but I do enjoy digging into a company's annual report to learn something new.
Johnson & Johnson: An Investment In A Healthcare Conglomerate That Cannot Go Wrong
It is putting in $30 million in a Band-Aid type ad campaign. This is the first time in a decade and its first global one ever that the company is indulging in a corporate re-brand ad campaign following recall of " millions of bottles and packages of Tylenol, Benadryl, Motrin and other over-the-counter medicines.
Is Johnson & Johnson Heading Off The Patent Cliff?
Patent expiration is one of the number one reasons for pharma companies' revenue deterioration.
Johnson & Johnson: Why I'm Cautious
If there was ever a stock that defined the buy and hold investment strategy it is Johnson & Johnson .
Sat May 11, 2013
Family Values Brand Uses Guns N' Roses to Revive Public Image
Weirdly, Guns N' Roses' "Sweet Child O' Mine" was recently softened as a nap-time lullaby for newborns.
Fri May 10, 2013
Johnson & Johnson: At The Crossroads - Part II
If current projections for dividend growth rate remained at 8.2% per year and those for net income growth rate at ~6% per year, it was shown to be inevitable that the dividend payout ratio would continue to increase.
Dividend Bubbles Are Not So Bad
With a lot of market bubbles that crop up in various sectors, the results are usually disastrous.
J&J, Ethicon finding growing surgical market in India amid obesity epidemic
Johnson & Johnson and its Cincinnati subsidiary, Ethicon Endo-Surgery, are benefiting from growing interest in obesity surgery in India, Bloomberg reports.
The Motley Fool
Should We Get Bullish on This Fast Growing Healthcare Company?
Anh is a member of The Motley Fool Blog Network -- entries represent the personal opinion of the blogger and are not formally edited.
Thu May 09, 2013
SEDASYS Propofol Sedation System Gets FDA Nod
Ethicon Endo-Surgery , a Johnson & Johnson company, announced that the FDA granted PMA approval for its SEDASYS device, the first computer-assisted personalized sedation system for use by clinicians in the endoscopy suites.
The Motley Fool
Is Buffett Bullish?
Nicholas is a member of The Motley Fool Blog Network -- entries represent the personal opinion of the blogger and are not formally edited.
New York Daily News
Johnson & Johnson get some of fashion's best lines
"Is the writer getting anxious?" Betsey Johnson asks. Well, sort of. The interview was supposed to start 45 minutes ago, but the famed fashion designer and her daughter Lulu are still sequestered in the back of Lulu's apartment, getting their hair and makeup done for the photo shoot.
Tue May 07, 2013
Johnson & Johnson Recall: Blood Glucose Meters
In March 2013, LifeScan, a division of Johnson & Johnson, announced a voluntary recall and replacement of approximately 90,000 blood glucose meters in the United States and nearly 2 million meters worldwide.
First Quarter 2013: Top and Bottom Performing Dividend Stocks
Investing in dividend growth stocks is a long-term proposition. One of the beauties of following a dividend growth strategy is that you don't have to watch your portfolio or the market on a daily basis.
Mon May 06, 2013
The Motley Fool
5 Dividend Stocks That Are as Safe as Treasuries
Meena is a member of The Motley Fool Blog Network -- entries represent the personal opinion of the blogger and are not formally edited.